From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum  by Langley, Paul C. et al.
Volume I·Number4·1998
VALUE IN HEALTH
From Research into Practice: How Should Healthcare
Organizations/Governments Decide about Lipid Therapy
and Who Will Pay? Reactor Panel and Open Forum
Paul C. Langley, PhD*; joel W. Hay, PhDt; [, Sanford Schwartz, MDt; Sidney C. Smith, MD§;
and james McKenney, PharmDl1
*University of Colorado Health Sciences Center. Denver, CO; tDepartment of Pharmaceutical Economics and Policy, University of
Southern California, Los Angeles, CA; *Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA;
'University of North Carolina at Chapel Hill;"Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
T his paper summarizes the questions and com-ments of conference attendants, following 2
days of presentations on pharmacoeconomic and
outcomes issues of lipid therapy, and focuses on
talks given during the final afternoon of the meeting
(see articles by S. Smith, P. Langley, J. McKenney,
N. Otten, P. Davey, D. Remund and E. Sutton, J.
Bonnette, R. Teagarden and R. Epstein, and W.
McGhan, this issue). What follows are reactions
and comments of the panel (P. Langley, J. Hay, J.S.
Schwartz, S. Smith, and J. McKenney) related to
the basis upon which healthcare organizations and
governments should decide about lipid therapy and
which parties should be responsible for payment.
Moderator: The floor is open to questions, of
which I am sure there are many after almost 2
days of stimulating presentations.
Stephen Boccuzzi (for J. Bonnette): A statement
was made that, in general managed care, clients
turn over about every 18 months. There has been
some preliminary data from the Rand Corpora-
tion showing that people with chronic diseases are
often more intensely ill and don't move between
plans as much as younger and healthier persons. I
wonder if you have any data from your own plan
about this. A second question relates to what kind
of outcomes metrics the panel thinks are appropri-
ate for decision-making purposes. I agree that deci-
sion-makers do not seem to use cost per life-year
saved; would cost per member per month perhaps
be important?
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James Bonnette: In terms of the turnover for the
plan, we haven't found too much difference among
age brackets for our plan. Typically, for instance,
Foundation Health, before the merger, was a small-
employer insurer with most of its businesses having
25 or fewer members. They would flip to another
plan every year or 6 months, if necessary, for price.
It was not age-dependent. For small employers,
price is the major issue. Larger employers are sub-
stantially more stable and the age range of its mem-
bers is more variable. HealthNet, for example, serves
many more large employers and has a different dis-
tribution of age; however, the turnover rate is rela-
tively the same. If you look at the different market-
places, turnover rates are different based on how
many health management organizations (HMOs)
there are, how competitive the marketplace is, and
how many of the same medical groups are on all of
the HMOs provider lists. If it is easy for a patient to
move from one HMO to another because the same
physician is on both plans, then that's what the em-
ployers find very easy to do.
In terms of the econometric issues, we did a num-
ber of studies with Paul Langley on how best to
model different chronic diseases and what the find-
ings implied for healthcare. Of all our results, what
made the biggest impact was information obtained
about asthma care. In evaluating how patients were
being treated for asthma, we demonstrated that by
getting closer adherence to guidelines, $36 million a
year would be saved in the state of California alone
on asthma. Given these findings, decision-making
was influenced so that expenditures for asthma
medications were increased with very fast payback:
within a year, one expects to save $36 million. This
was the only one of our studies that received atten-
tion from senior management. The others did not get
very much attention because they involved costs that
resulted in benefits only after a longer period of time.
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Jerry Avorn (for J. Bonnette): What you describe
sounds like a failure of market mechanisms to get
the best possible healthcare to the largest number of
people in' a profit-driven, managed care environ-
ment. If we all agree that it is better not to have a
myocardial infarction (MI) than to have one, and
that it's better to be able to prevent an MI with
medications if it can be done, and if the current sys-
tem is really not motivated to move managed care
patients in that direction effectively and in large
numbers, what's next? And what about this funny
intermediary, the employer, who is in the middle?
Even if there were some concern about patients not
wanting to use a managed care organization that
did not allow good primary or secondary preven-
tion, it is not clear that the employers are terribly
concerned about it, especially if their time horizon is
so short.
James Bonnette: I think that both the for-profit
and the not-for-profit organizations have to func-
tion by the same mechanism. This could work if
they were held accountable to a standard. The prob-
lem is that healthcare has been financed in different
ways and responsibilities have shifted, but no one is
being held responsible, neither physicians nor the
health plans. No one measured performance of plans
until organizations such as the National Committee
on Quality Assurance (NCQA) raised the bar. They
put forth a group of process measures that people
should have been following for a long time, and to
stay in business, this is the least that has to be done.
That is a great start, but it is nowhere near what we
would like to see. If there were effective basic stan-
dards that health plans had to meet, total costs
could be calculated and there would not be a differ-
ence between the price on the different HMOs, state
to state. With Medicare, capitation payments across
the country will be equalized over the next 6 years,
making these numbers relatively even. A minimum
standard set of benefits, and measures to those ben-
efits, can be set in place for which people would be
held accountable. For instance, Medicare could de-
mand to know the name and the percentage of the
patients who had mammograms in 5-year intervals
who are enrolled in a plan, and if the plan could
not provide that, they would not get paid. That is a
tremendous incentive to be able to spur on a plan to
decide the cost of doing business. It would make a
change right away and still provide competition,
which tends to hold prices down to a significant de-
gree. For the employers, more purchasing coopera-
tives will be asking for standards that all plans have
to meet. Small businesses will not be paying any
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more than large companies on a per-member-per-
month basis, but probably would opt for basic cov-
erage rather than more elaborate alternatives.
With drugs and new therapies becoming more
expensive, there will be some difficult decisions to
make, decisions that I cannot see being made the
way we are currently organized. We seem to make
political decisions all the time, whether we like to
admit it or not; and it seems to be predominantly
the way many drugs get on the formulary, such as
Prozac or certain medications for asthma or AIDS.
To make lipids an important issue, one needs to
make it an important political issue and make sure
that patients really care about it. I want you to
know that the number one prescribed drug for pa-
tients who have cardiovascular disease is Prozac; it
is prescribed 5 to 10 times the rate of appropriate
medications, and something should be done about
this.
Joel Hay: The notion that managed care is not
going to pay for something unless there is a pay-off
in financial profit terms in the next quarter is quite
astounding. In addition to all the regulatory mech-
anisms we have in the United States, there is also a
flourishing legal system that has lawsuits running
rampant. Furthermore, there is a legal obligation
to the patient. If one talks about lipid therapy-in
this case, a drug for primary prevention that is
proven to save lives-how can patients be denied
wide access to this medication? This issue is not
confined to the United States; the British and Ca-
nadian guidelines do not seem to be any better in
terms of primary prevention. Our research shows
that primary prevention lipid-lowering therapy is
cost-effective at cardiovascular risk levels as low as
1% per year. I think we have a major problem in
terms of the conception of how guidelines should
be implemented, whether by a government system,
a for-profit organization, or anything else.
Peter Davey: To address the legal point, from the
United Kingdom's perspective, we are not usually
so vulnerable to lawyers as in the United States;
however, if the government had said that we should
be treating in a certain way and then doctors do not
follow the recommendation, doctors are going to
be legally responsible.
Nicolaas Otten: In the Canadian setting, funds
are not available to cover care for a specific indica-
tion across the board, so care starts at a certain
level, which tends to be for those at higher risk for
the disease. We can talk about treating the whole
group all we want, but there is an up-front cost as-
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sociated with it; the financial benefits to the system
occur down the road. We can only take one step at
a time according to what budgets will allow. So
treating a small percentage properly is a good start.
The reality is that treating those at lower risk levels
will double or triple the cost for the plans and chew
up the whole Pharmacare drug budget.
On another topic, as a non-American, I found
the role/function/mandate of the pharmacy benefit
managers (PBM) confusing and unclear. We are
given a number of programs without a clear indi-
cation as to the purpose of trying all these pro-
grams. Criticism is laid down over quality-adjusted
life-years (QALYs) but no insight as to what pay-
ers might be interested in evaluating. It is a bit like
the classical case of making decisions based on
population impact versus making decisions about
each individual case. It is interesting to note the
discussion of quality indicators by Sidney Smith
versus the viewpoint of R. Teagarden.
Moderator: I have been surprised at how many
economists at this meeting have said that lipid-
lowering treatment is cost-effective or is not. When
I was taught economics, things could only be cost-
effective in comparison to something else. I think
this notion that there is some threshold at which
things become cost-effective is not helpful in deci-
sion-making because it is the budget that counts.
Cost per year is what we have to worry about.
Speaker 1: Before we say that primary prevention
should always be paid for, we have to realize that
there are some payers that simply don't have very
much money. They want to do as much as they can
and they have to make decisions to pay for some
things and not others.
James Bonnette: To go back to the legal question,
managed care plans do put statins on their formu-
laries; however, there is no restriction on how phy-
sicians write prescriptions for them. Plans are good
risk managers, but the legal liability falls on the
backs of the physicians.
Speaker 2: Why don't managed care plans set per-
formance standards in their contracts with physi-
cian groups?
James Bonnette: We do have some set perfor-
mance standards, but they are standards that we
recommend but cannot enforce. We are not in a
position to hire or fire physicians or measure how
standards on treatments are met.
Speaker 3 (for R. Teagarden): Regarding second-
ary prevention when lipid-lowering therapy is initi-
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ated after a cardiovascular event has occurred: de-
spite this event, it seems that, whatever the input
intervention, compliance is not managed well. Can
you talk about some of the things that Merck-
Medco, as a pharmacy benefit manager, does to in-
sure compliance after secondary prevention? Does
intervention or education work well?
Russell Teagarden: We do have programs in place
to monitor compliance, but only if a plan wants it.
Some choose to put a drug on their formulary and
let things happen in due course. If a plan does want
follow-up, we do have systems to provide informa-
tion on how well patients are taking their medica-
tions, who may be dropping off and find out why.
We can address these issues very specifically, assess-
ing practice and identifying the barriers to compli-
ance. We determine through different psychological
constructs what the cause of a patient's noncompli-
ance may be, and we then offer these patients re-
sponses or ideas that are specific to their individual
compliance barrier. This is provided on a regular
basis, perhaps through phone calls or mailings, and
we continue to monitor and brief their physicians in
the process. Plans may opt for this service when they
want to see the utilization of a drug go up now, be-
cause they believe that the treatment will reduce
other health complications and costs in the long
run. They believe that immediate efforts will payoff
in the end.
Susan Andrade (for N. Otten): In your presenta-
tion, we saw the Canadian guidelines for men from
ages 40-70 and for women from ages 50-70. What
happens after 70?
Nicolaas Otten: There is a lot of controversy in
terms of whether to treat or not to treat after 70
years of age. There is a general lack of good data be-
cause most trials don't extend into these age groups,
so, there is not presently a consensus in terms of the
guidelines for those over 70.
Speaker 4 (for D. Remund): The military offers
an interesting system that one can view almost as a
large-staff model HMO with one transient set of
providers and patients who rotate; and concur-
rently, career people who stay around 20 or 30
years. Considering that combination, can you offer
any insights from the military perspective, especially
at a policy level with the Department of Defense or
even within the reality of your experience with dif-
ferent military treatment facilities?
Daniel Remund: It is a unique model. With some-
thing like statin therapy, I think we have incentives
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in place to use those drugs to prevent events from
occurring at a later date, which are better than any
other patient population or provider organization.
Persons who begin statin therapy in our system have
probably been in the military for some time, so they
are likely to be in our system for the rest of their
lives. But who makes the decisions in the end? Ulti-
mately, it is the taxpayer who makes the decisions.
Your congressmen, your senators vote on the de-
fense budget and that budget is divided in so many
ways. No matter how cost-effective something is, or
how much we think it is going to benefit somebody
clinically, if the defense healthcare budget comes
down to a certain number of dollars, priorities for
funding have to be set. The military system has the
incentives in place, but how do we maximize the
use of our budgets? Theory would tell us that if
there is unnecessary variation in such a system, one
should work hard to eliminate it. If we have 110
military facilities making independent formulary
decisions, it is not efficient if we are trying to provide
a consistent assistance benefit across the system. We
should try to make the best possible uniform deci-
sion based on the clinical and economic analysis.
James Bonnette: We cover outpatient services out-
side the military treatment facilities through the
Civilian Health and Medical Program of the Uni-
formed Services (CHAMPUS). A set of benefits is
provided by the military treatment facilities now,
but there is also an open formulary outside of the
military treatment facilities. If a drug is not available
through the military treatment facility, patients can
go to a pharmacy outside the facility, and it is cov-
ered under the plan we provide. There is no specific
restriction under this Tri-CARE program. We are
not allowed to have a formulary as a vendor outside
the Department of Defense. A rapid growth appears
to be happening in the CHAMPUS or Tri-CARE
population outside military treatment facilities, al-
most triple the rate of growth of any other segment
in the country for pharmacy benefits.
Speaker 5 (for P. Davey): Statin intervention is
currently going through a massive regulatory change
in Europe, and centralized procedures for MIs are
increasing among the 15 member states. There is
also a council directive to register medical prescrip-
tions according to restrietlnonrestrict, renewable!
nonrenewable, speciallnonspecial medical prescrip-
tion categories. Can you comment on this? Sec-
ondly, I have heard that the European Athroscle-
rotic Society has guidelines for Europe; can you
comment on these guidelines and compare them to
those in the United Kingdom?
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Peter Davey: Much European legislation on drug
registration is being passed. It is becoming more
centralized and that likely will be increasing.
There is an effort to harmonize various aspects of
drug therapy. There are supposed to be standard
Prescribing Analysis and Cost (PACT) sizes in Eu-
rope, but the UK is probably going to pass its own
legislation because the UK system is organized dif-
ferently. Our lengths of treatment do not fit the
European PACT sizes. With the European harmo-
nization, if a member country passes legislation to
opt out, then they can do so, but I believe this type
of harmonization will be difficult to achieve. So,
legislation is being passed, but whether it will
carry through is a different matter. With respect to
the European guidelines on statins, it seems they
would result in fewer patients being treated, par-
ticularly for primary prevention, than with the UK
government directive, assuming that UK physi-
cians implement their guidelines.
Moderator: We'll pause from questions now and
convene the reactor panel, including Joel Hay,
James McKenney, Sanford Schwartz, Sidney Smith,
and myself [Paul Langley].
Joel Hay: Today's session has been extremely use-
ful but, for me, a bit disappointing or even depress-
ing to know how real-world decisions are made
and how little attention people pay to the really
nice pharmacoeconomic models that we dream up
sitting in our ivory towers. There are different ap-
proaches to getting guidelines in place in the United
States and perhaps in other countries where market
systems can be relied on. The big tension anywhere
in the world is: If you have something that you be-
lieve works-and after this meeting everyone
would have to agree that statin therapy does work
in preventing heart disease--and if it is cost-effec-
tive-and, again, evidence is very substantial that
these therapies are cost-effective relative to other
uses of healthcare dollars-then why is it not being
used to its greatest potential?
As we deal with the tensions of moving from the
knowledge base to treatment and practice in the
real world, rather than using government regula-
tions, which have limited effectiveness, perhaps we
should follow other industries for developing a
kind of self-regulatory market structure. Dr. Bon-
nette mentioned some of the voluntary organiza-
tions that can form an established credentializa-
tion; it seems to me that health plans need to move
in the direction of establishing credibility on the
basis of what they provide to the consumer. To
take a lead from the automotive industry, which
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produces both economy cars and Cadillacs, the
healthcare industry will have its share of low-cost!
low-benefit plans right up to top-of-the-line plans.
It will be up to each plan to provide information so
that people can make choices as to whether or not
the particular model they have is what they want.
We cannot expect the patient to understand every in-
tricacy of how the decisions are made, what drugs
are on the formulary, what drugs are not, and/or
what types of surgeries are covered, but they can
make decisions based on overall reputation. If a plan
tries to set itself up as top of the line of the healthcare
industry, and maybe goes a few extra steps to make
sure that it provides reasonable, rational, cost-effec-
tive interventions, many people will buy into that
kind of a plan. If other plans want to be economy
versions, that would be up to them. In countries that
have single-tier healthcare systems, the options will
be more limited. I think there are ways of doing this
within the context of a market system, and there will
always be some tension between regulatory ap-
proaches and market approaches.
James McKenney: I served on the National Cho-
lesterol Education Program's (NCEP) panel that de-
veloped the guidelines that we are trying to imple-
ment with so much difficulty. These guidelines were
developed with considerable input from many
knowledgeable and insightful people with the point
of view that LDL cholesterol reduction is key. After
the guidelines were released, studies such as the West
of Scotland Coronary Prevention Study (WOSCOPS)
[1], the Scandinavian Simvastatin Survival Study
(4S) [2], and the Cholesterol and Recurrent Events
(CARE) [3] trials affirmed the guidelines. We will
soon hear about other lipid trials, in particular one
from Texas [4] that will confirm that LDL choles-
terol reduction is key. High density lipoprotein cho-
lesterol (HDL-C) and triglycerides, which some are
touting as important, have not been tested suffi-
ciently. If one reduces LDL cholesterol far enough,
risk due to low HDL-C and triglycerides is mini-
mized. Populations with naturally low cholesterol
because of habits or genetics, even if hypertension is
present, have little heart disease. The LDL choles-
terol is a key and its reduction is key. Cholesterol
and HDL-C ratios offer areas for scientists to de-
bate, develop hypotheses, and further test, but we
are not ready to change the formulary based on ra-
tios just yet. I would like to emphasize that the
NCEP thinks the current guidelines are still the
right ones.
New guidelines are not likely to come out for
some time. The current guidelines have not even
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been fully implemented as yet, and still new trials
are affirming them. The NCEP plans to develop
white papers on areas that need comment, such as
the treatment of diabetes. We need to emphasize
that treatment must be more aggressive in the dia-
betic population. We need to clarify HDL-C and
triglyceride-rich lipoprotein issues. We should lis-
ten carefully to the Europeans and their use of glo-
bal risk. Rather than identifying high blood pres-
sure or low HDL-C as discrete variables, use of
continuous variables to develop a unique risk score
for each patient upon which to base decisions is
needed. I think this will be the subject of the white
paper and probably the foundation for change in the
new guidelines when they come about.
Another important concept is that the NCEP
does regard the treatment of hypercholesteremia
from a societal point of view, considering both the
population and the individual patient. The guide-
lines we are discussing have been developed for in-
dividual patients and drive decision-making at a
provider level. They were very strongly influenced
by an economist on our panel. We were challenged
by cost-effectiveness issues as we thought through
the recommendations. In this respect, the guidelines
and the cut points for treatment were very much in-
fluenced by the near-term risk of events; that is,
events occurring over the next 5 or 10 years, and
not the long view, not even for primary prevention.
Using current guidelines, we now have to wait for a
person to develop a high enough risk to intervene. I
would like to challenge all of us to think more in
the long view for prevention. The patient with fewer
than two risk factors in the judgment of the guide-
lines is not currently a candidate for drug treatment,
but rather for lifestyle modification. Mean choles-
terollevels have dropped over the last 10 years in
the United States, and that has probably translated
into enormous savings from the reduction in mor-
bidity and mortality from coronary heart disease. It
is this approach that ultimately is more important
than treating the high-risk patient. The charge be-
fore us may be to use pharmacoeconomic informa-
tion to determine which patients to treat, but we
really need to consider the population and the im-
pact of preventive measures over the long term.
Moderator: One of the issues that has not been re-
solved is the range of behavior between different
managed care groups. Joel Hay raised the point
that in a market mechanism some people will prefer
to bicycle, other people prefer to walk, some will
prefer driving Cadillacs. Putting the important issue
of equity to one side, we must translate the results
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we have heard at this meeting. There is no doubt
that lipid-lowering drugs work and can have an im-
pact on cardiovascular disease. They have consider-
able value, but to what extent does managed care
want to take that value on board? There is a range
of managed care groups with different disease man-
agement strategies in the marketplace. They all ar-
gue that they intervene in different disease states,
but the evidence to support what effects their strat-
egy will have, not only on costs but on outcomes of
treating patients, is rarely forthcoming. We need to
broaden the basis of pharmaceutical economics, to
move away from an incremental cost outcomes ap-
proach and closer to a more systems-oriented im-
pact. This means that, within the context that
healthcare is being delivered, what would be the
most cost-effective strategy for intervening with pa-
tient groups, in particular managed care popula-
tions? These questions require details from health-
care systems as to the type of information they need
to modify behavior of patients and physicians. It
also applies to coming back to the physician's office
and the physician's incentive to deliver appropriate
healthcare in the long term. Studies are showing
massive benefits for the treating population from
lipid-lowering therapies in a shorter period of time
than 5 years. Incentive structures and the way in
which healthcare is organized have to be consid-
ered. It might be useful to think about integrating
particular healthcare environments with managed
care systems or provider systems to produce a sig-
nificant benefit. In the long term it's going to be
costs versus costs, and there will be cost savings
over a 5-year time frame for these healthcare sys-
tems. We must start thinking about the organiza-
tion of healthcare systems and how we can demon-
strate the benefit of research studies to the real-
world treating environment. If not, we will still be
faced with the same managed care systems that
only think about the next quarter's financial re-
turns-but these systems are rapidly going out of
favor and alternatives need to be offered.
Speaker 6 (in response to]. Hay): It is true that
we do let people choose between whether they
drive an economy car or a Cadillac, but at the same
time a decision was made many years ago that the
government would not allow car manufacturers to
make cars that are inherently unsafe. There are re-
quirements and standards to be met. So, seat belts
have to be provided, even if you could save a few
dollars on the purchase price without them. We
have many HMOs that people can choose to belong
to, but they need standards. Every HMO would be
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legally required to meet these standards and go be-
yond them. Whoever can do this efficiently will
prosper and expand. A combination of market ver-
sus regulatory forces is what we may ultimately
need.
Speaker 7: Have we, as health economists, done
enough in lipid-lowering therapy to date? I think
we have so far only done part of our job. We are in
a situation where cost-effectiveness and costs in an
economy with fixed budgets are relevant, and we
have shown that, with introduction of new treat-
ments, costs will increase. To do the next part of
our job and move the field forward, we need to
study willingness to pay. Are people willing to pay
the additional costs of the system?
Moderator: Perhaps health plans will have a pre-
ventive supplement to the standard benefits pack-
age for which one would pay. This brings up the
significant issue of equity, which no one has really
addressed. If we as individuals opt to pay more for
healthcare, some people will be able to pay and
others will not. Demand for and access to health-
care for different socioeconomic groups is a key is-
sue in the organization of the system.
Speaker 8: It appears that we have a healthcare
system that is not meeting its responsibility to pa-
tients and a managed care environment without
the commitment to change it. Perhaps health econ-
omists could help us by presenting models of how
we could better use the resources we have to de-
liver services that address effective treatment strat-
egies and long-term compliance.
Moderator: There are many economic models
that health economists have yet to employ in this
area. If you look upon the lack of healthcare in re-
lation to the public good, there are models to
show how you can legally change the environment
to minimize the cost to the community of such
things as poor access to healthcare and lack of in-
formation about healthcare.
Peter Davey: Equity is an important issue that is
often talked about but not treated very realistically.
Allan Williams, in an article appearing in Health
Economics [5], makes the very realistic point that
people with lower socioeconomic status have poorer
health. It is very likely that there is less health gain
per dollar spent in that group than in middle-
income groups or higher-income groups. A choice
has to be made to be either equitable or efficient,
but you probably cannot be both.
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Speaker 9: I have heard several times today that
pharmacoeconomics has not lived up to its poten-
tial. Maybe some food for thought would be that
managed care has not lived up to its potential or
allowed pharmacoeconomics to do its best as a
science. Pharmacoeconomics evolved as a result of
managed care. Mr. Bonnette has said several times
that the systems to ensure access to statins in man-
aged care are not necessarily in place. Is this be-
cause of an operations problem, are the systems
just not there, or is it a problem of not being will-
ing to finance statin use according to guidelines af-
ter looking at databases and at outcomes data?
James Bonnette: It's actually some of all of those.
The data resides there but there has been no partic-
ular incentive to use it.
Speaker 9: To optimize the relevance of results
from the pharmacoeconomic studies for translation
to practice, we need to be able to utilize the out-
comes data that both we and managed care organi-
zations have.
James Bonnette: Results from a number of phar-
macoeconomic studies have been used fairly exten-
sively for formulary decisions, but one must use a
pharmacoeconomic study in the way it has been de-
signed. In using them to influence decision-making,
the difficulty remains that one can set up all kinds of
guidelines, but if you don't measure against them,
you do not get any benefit. We have used some as
standards and measured in comparison to them,
finding significant changes in physician behavior. As
long as the bar is raised for everybody and one mea-
sures against the standards put forward, then the
studies becomes an acceptable cost of doing busi-
ness. It can be calculated and translated to per-mem-
ber-per-month costs and plans changed accordingly.
Moderator: So what is to stop groups such as the
one you are with actually setting those standards?
Minimum standards for managed care, minimum
reporting or monitoring standards and make sure
the guidelines are put in place?
James Bonnette: I do not think that there is any-
thing hindering managed care organizations from
doing that. Taking a page from the Prozac book,
publicity will get people behind your position. If
that is what the public wants, that is what we
would do. There is nothing altruistic about a busi-
ness of this type and this magnitude. Healthcare in
this country is a huge business. Collectively, HMOs
are an enormous industry employing many people.
If we have to alter ourselves to stay around, we will.
249
Speaker 10: I would like to call upon the pharma-
ceutical industry to take some accountability for
providing resources to assist patients in making the
correct decision. Instead of just marketing a medica-
tion, why not attach information on the benefits of
the medication to this disease? There needs to be a
concerted effort to educate patients, and the phar-
maceutical industry seems to have the most re-
sources and to be the best placed to do this.
Susan Andrade: Just a final comment. Mandated
benefit, which levels out the competition, has not
been good for our economy. We are struggling to
get out of a recession and I do not know how re-
ceptive the legislature or the business community
would be to a mandated benefit.
Moderator: Thank you for your questions and
comments. I will now ask Joel Hay to take the po-
dium to wrap up this session.
Joel Hay: I, for one, am very pleased with the ac-
complishments of this conference. There have been
intellectually stimulating presentations in the clinical
area, the pharmacoeconomic modeling area, and in
applications to real-world practice. I hope that
ISPOR can continue to conduct disease-specificcon-
ferences of this nature because they have a lot of
value and merit.
Where do we need to go from here? We need to
move more in the area of translation into practice at
every level, including clinical, pharmacoeconomic
modeling, and health decision-making. We have
to find better systems to put these findings into
practice. We need better data systems for collect-
ing actual outcomes data on patients for doing the
kinds of studies necessary for pharmacoeconomics
and outcomes research.
Future conferences of this type should have more
information on rigorous assessments of quality of
life and health status improvements. Also needed are
willingness-to-pay estimates and improved method-
ology for assessing willingness to pay. Issues of
equity and equitable distribution of resources are
areas fruitful for investigation in lipid pharmaco-
economics.
Finally, the development-both locally and na-
tionally, and possibly internationally-of consor-
tiums to do legitimate outcomes studies in the real
world would be a positive next step. Studies of
head-to-head comparisons of different drugs, dif-
ferent statins, and other therapeutic interventions
for lipid-lowering could be carried out in a real-
world context if consortia of managed care organi-
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zations, academic and other research investigators,
and pharmaceutical companies agreed to partici-
pate. If the studies were designed, not at the level of
clinical rigor required for an FDA submission, but
rather done in the context of real-world treatment
versus usual care, data collection would be totally
passive with no additional services provided as a re-
sult of protocol. The only additional step needed
would be randomization of patient to treatment.
That done, data would be collected and how pa-
tients fare with different treatments would be as-
sessed. One could look at different compliance pro-
grams, patient education programs, and screening
intervention programs at a much lower cost per pa-
tient than typically happens in gold-standard clinical
studies. I think if we as pharmacoeconomists and
outcomes researchers want to answer these ques-
tions, not just do models based on panels of experts,
but generate real data, we have to reduce the cost of
these studies to reasonable levels. Why not do them
as a collaborative effort in a consortium of managed
care rather than in one managed care organization?
There are still many things we need to learn.
Network with people that you've met at this con-
ference to move this field forward. And consider
that during our 2 days at this conference, airbags
in cars have saved one life in the United States,
whereas 3000 Americans have died of coronary
heart disease. Of those 3000 patients, probably
1000 could have been saved with lipid therapy that
Reactor Panel
sits on the pharmacist's shelf, approved and mar-
keted, but unused.
Moderator: Thank you for all attending this inter-
esting conference and participating in the stimulat-
ing discussion during this final session.
This article was prepared with the assistance of BioMed-
Com Consultantsinc., Montreal, Canada.
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